Movement Alert｜SKB BIO Rises 3.89% in Regular Trading, Innovation Drug Overseas Licensing Momentum Supports Sentiment

Market Focus10-23 10:23

On October 23, SKB BIO rose 3.89% in Regular Trading, trading at HK$464.4, with turnover of HK$184 million.

The move coincided with continued market support for innovative drug names after strong overseas licensing data for Chinese innovative medicines reinforced expectations for global value realization.

Background context indicates that China’s innovative drug outbound licensing value reached about $130 billion in the first three quarters, close to the full-year level of last year. At the company level, first-half revenue was RMB978 million and adjusted net profit was RMB479 million, marking its first profitable half since listing. In addition, SKB378/WIN378 reported positive phase 2 interim data in asthma and has already entered phase 3, adding support to pipeline monetization expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment